Tian Zhang, Associate Director of Clinical Research at the Simmons Comprehensive Cancer Center, shared a post on X:

“Traveling with mixed emotions to ASCO 25 this year. Celebrating science and the years of dedication, work, and patient contributions to cancer clinical trials. But science itself is under attack – defunding of preclinical discovery work will end up slowing our clinical advances.

At the center of next few days ASCO 25: our patients. And — if we face our humanity, ourselves – as we age and deal with cancer. Nothing harder in my clinic than telling a patient “there are no more treatment options”. Every trial gives hope and every new drug gives more time.

That’s what we all want with this brief time on earth – More time to be productive. More time to see the world. More time with loved ones.”

More posts featuring Tian Zhang on OncoDaily.

Every Trial Gives Hope: Tian Zhang Shared Reflections Ahead of ASCO 2025

“Traveling with mixed emotions to ASCO 25 this year. Celebrating science and the years of dedication, work, and patient contributions to cancer clinical trials. But science itself is under attack – defunding of preclinical discovery work will end up slowing our clinical advances.

At the center of next few days ASCO 25: our patients. And — if we face our humanity, ourselves – as we age and deal with cancer. Nothing harder in my clinic than telling a patient “there are no more treatment options”. Every trial gives hope and every new drug gives more time.

That’s what we all want with this brief time on earth – More time to be productive. More time to see the world. More time with loved ones.”